MKResearcher profile · from public sources
Marina Konopleva
Targets
Filled chips are declared by the researcher; the others come from publications (number of works).
Now
Trials, publications and grants since Nov 2024.
Publication
CC-486 plus venetoclax: another step toward oral AML therapy.
Blood advances, Oct 2026
Publication
Long-term outcomes of azacitidine, venetoclax, and gilteritinib in newly diagnosed FLT3-mutated AML.
Blood advances, Sept 2026
Publication
LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models.
Blood cancer discovery, Sept 2026
Publication
Genomic Subtype Influences BH3 Mimetic Drug Sensitivity and Synergy with Cytotoxic Chemotherapeutics in T-cell Acute Lymphoblastic Leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research, Jul 2026
Publication
CD64 enables TCR-dependent, MHC-independent CTL cytotoxicity of AML cells.
Proceedings of the National Academy of Sciences of the United States of America, Jul 2026
Publication
Anti-apoptotic BCL-2 family proteins: from regulatory networks to therapeutic targeting.
Oncogenesis, Jun 2026
Publication
A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemia.
Leukemia, Feb 2026
Publication
TP53 loss traps AML in XPO7-NPAT nuclear transport fraud.
Blood, Feb 2026
Publication
Rapid clonal selection within early hematopoietic cell compartments presages the outcome of ivosidenib combination therapy.
Blood, Feb 2026
Publication
Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.
Leukemia, Jan 2026
Publication
Blastic plasmacytoid dendritic cell neoplasm (BPDCN): international, multi-center collaboration and global registry program.
Discover oncology, Dec 2025
Publication
The LSC17 score: a prognostic biomarker now validated for real-world clinical application in acute myeloid leukemia.
Haematologica, Dec 2025
Publication
A phase 1/2 study of DS-1594 menin inhibitor in relapsed/refractory acute leukemias.
Journal of hematology & oncology, Nov 2025
Publication
Menin inhibitor DS-1594b drives differentiation and induces synergistic lethality in combination with venetoclax in acute myeloid leukemia cells with rearranged mixed-lineage leukemia and mutated nucleophosmin-1.
Haematologica, Nov 2025
Publication
Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis.
Clinical cancer research : an official journal of the American Association for Cancer Research, Jun 2025
Publication
Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Jun 2025
Publication
VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome: long term follow-up of a phase 2 trial.
Blood cancer journal, Apr 2025
Publication
DNTT-mediated DNA damage response drives inotuzumab ozogamicin resistance in B-cell acute lymphoblastic leukemia.
Blood, Mar 2025
Publication
Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia.
Blood advances, Feb 2025
Co-authors
Who links you
Enter another researcher's profile link or ID to see who has published with both of you.
You have published with Courtney D DiNardo directly.
- GTGuilin Tang5 works together here · 8 with Courtney D DiNardo
Is this you? Request a correction or removal: support@frontlightresearch.com
Report an error